Reduction of immunosuppression for transplant-associated skin cancer: expert consensus survey
- 26 January 2006
- journal article
- review article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 154 (3), 395-400
- https://doi.org/10.1111/j.1365-2133.2005.07087.x
Abstract
Reduction of immunosuppression is considered a reasonable adjuvant therapeutic strategy in solid-organ transplant recipients experiencing multiple or high-risk skin cancers. However, the literature provides no guidance about what threshold of cancer development would warrant initiation of reduction of immunosuppression.To develop expert consensus guidelines for initiation of reduction of transplant-associated immunosuppression for solid-organ transplant recipients with severe skin cancer.An expert consensus panel was convened by the International Transplant Skin Cancer Collaborative and Skin Care for Organ Transplant Patients Europe Reduction of Immunosuppression Task Force. Thirteen hypothetical patient scenarios with graduated morbidity and mortality risks were presented and mean and mode expert opinions about appropriate level of reduction of systemic immunosuppression (mild, moderate, severe) were generated.Mild reduction of transplant-associated immunosuppression was considered warranted once multiple skin cancers per year developed or with individual high-risk skin cancers. Moderate reduction was considered appropriate when patients experienced > 25 skin cancers per year or for skin cancers with a 10% 3-year risk of mortality. Severe reduction was considered warranted only for life-threatening skin cancers.Reduction of immunosuppression is considered a reasonable adjuvant management strategy for transplant recipients with numerous or life-threatening skin cancers. Proposed guidelines are presented for the graduated reduction of immunosuppression coincident with the increasing skin cancer risks.Keywords
This publication has 35 references indexed in Scilit:
- Two‐year incidence of malignancy in sirolimus‐treated renal transplant recipients: results from five multicenter studies*Clinical Transplantation, 2004
- Skin Cancers after Organ TransplantationThe New England Journal of Medicine, 2003
- Successful treatment of post-transplant Kaposi's sarcoma by reduction of immunosuppressionNephrology Dialysis Transplantation, 2002
- NO RECURRENCE OF POSTTRANSPLANTATION KAPOSI???S SARCOMA THREE YEARS AFTER RENAL RETRANSPLANTATIONTransplantation, 2002
- N-TERMINAL FRAGMENTS OF THE PROATRIAL NATRIURETIC PEPTIDE IN PLASMA AND URINE OF KIDNEY GRAFT RECIPIENTSTransplantation, 2001
- Management of Epstein–Barr Virus-induced Post-transplant Lymphoproliferative Disease in Recipients of Solid Organ TransplantationAmerican Journal of Transplantation, 2001
- Are heart transplant recipients more likely to develop skin cancer than kidney transplant recipients?Transplant International, 2000
- Are heart transplant recipients more likely to develop skin cancer than kidney transplant recipients?Transplant International, 2000
- Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip: Implications for treatment modality selectionJournal of the American Academy of Dermatology, 1992
- Epstein–Barr Virus-Induced B-Cell Lymphoma after Renal TransplantationThe New England Journal of Medicine, 1982